Search results
Results from the WOW.Com Content Network
DMBA is widely used in many research laboratories studying cancer. DMBA serves as a tumor initiator. Tumor promotion can be induced with treatments of 12-O-tetradecanoylphorbol-13-acetate (TPA) in some models of two-stage carcinogenesis. [3] This allows for a greatly accelerated rate of tumor growth, making many cancer studies possible.
IARC group 2B substances, mixtures and exposure circumstances are those that have been classified as "possibly carcinogenic to humans" by the International Agency for Research on Cancer (IARC) as [1] This category is used when there is limited evidence of carcinogenicity in humans and less than sufficient evidence of carcinogenicity in experimental animals.
Binimetinib, sold under the brand name Mektovi, is an anti-cancer medication used to treat various cancers. [4] Binimetinib is a selective inhibitor of MEK, a central kinase in the tumor-promoting MAPK pathway. [5]
Bendamustine, sold under the brand name Treanda among others, is a chemotherapy medication used in the treatment of chronic lymphocytic leukemia (CLL), multiple myeloma, and non-Hodgkin's lymphoma. [ 3 ] [ 4 ] It is given by injection into a vein .
The Koch reaction is an organic reaction for the synthesis of tertiary carboxylic acids from alcohols or alkenes and carbon monoxide.Some commonly industrially produced Koch acids include pivalic acid, 2,2-dimethylbutyric acid and 2,2-dimethylpentanoic acid. [1]
Monomethyl auristatin E is an antimitotic agent which inhibits cell division by blocking the polymerisation of tubulin.The linker to the monoclonal antibody is stable in extracellular fluid, but is cleaved by cathepsin once the conjugate has entered a tumor cell, thus activating the antimitotic mechanism.
Dynemicin A is an antitumor natural product isolated from Micromonospora chersina which causes DNA strand cleavage. Iwasaki et al. first studied the biosynthetic pathway of Dynemicin A by 13 C NMR labeling experiments. [2]
Tucatinib, sold under the brand name Tukysa, is an anticancer medication used for the treatment of HER2-positive breast cancer. [ 3 ] [ 4 ] It is a small molecule inhibitor of HER2 . [ 6 ] [ 7 ] It was developed by Array BioPharma and licensed to Cascadian Therapeutics (formerly Oncothyreon, subsequently part of Seattle Genetics ).